AKT1 and neoplasm: Metformin treatment inhibits Akt signaling and increases AMP-activated protein kinase, which inhibits mTOR, in addition to activating the transcription factor FOXO3, a tumor suppressor that promotes differentiation and is often phosphorylated and silenced by AKT in GSCs [242].